Braavos Investment Advisers is a London-based venture capital firm managing over $500M, investing in companies founded on the premise of scientific breakthroughs. The firm focuses on early- to growth-stage deeptech companies, particularly those originating from institutions such as the University of Oxford.
Their most common stage is series-a (75% of deals). Average disclosed round size is $46.9M (across 5 rounds with reported amounts).
Portfolio
8
Fund Size
$500M
Top Stage
Series A
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Wild Bioscience | Series A | — | Oct 2025 |
 Salience Labs | Series A | $30M | Feb 2025 |
 PQShield | Series B | $37M | Jun 2024 |
 Oxford Ionics | Series A | — | Jan 2023 |
 Charm Therapeutics | Series A | $50M | Jun 2022 |
 SpyBiotech | Series A | $32.5M | Feb 2021 |
 Osler Diagnostics | Series C | $85M | Jan 2016 |
 Oxford Ionics | Series A | — | — |
Top Co-Investors
Oxford Science Enterprises7 shared
Lansdowne Partners3 shared
Torch Capital2 shared
2xN2 shared
Prosus Ventures2 shared
Oxford University2 shared
F-Prime Capital1 shared
General Catalyst1 shared
AXIAL Partners1 shared
OrbiMed1 shared
Khosla Ventures1 shared
Applied Materials1 shared
Silicon Catalyst Ventures1 shared
Cambridge Innovation Capital1 shared
ICM HPQC Fund1 shared
Hermann Hauser Investment1 shared
Blue Sky1 shared
Arm Holdings1 shared
Legal & General1 shared
Last updated: 20 October 2026